Halozyme Therapeutics, Inc. announced that Takeda received European Commission (EC) approval for HYQVIA®? [Immune Globulin Infusion 10% (Human)] co-formulated with Halozyme's ENHANZE®? drug delivery technology as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy (CIDP) after stabilization with intravenous immunoglobulin therapy (IVIG).

HYQVIA®? also recently received U.S. Food and Drug Administration (FDA) approval as maintenance therapy for adults with CIDP. HYQVIA®?

is the only FDA and now EC-approved combination of immunoglobulin (IG) and hyaluronidase for CIDP and is administered by facilitated subcutaneous infusion. For patients with CIDP, HYQVIA®? can be infused up to once monthly (every two, three or four weeks).

HYQVIA®®? can be administered by a healthcare professional or self-administered in the patient's home after appropriate training. The centralized marketing authorization for HYQVIA® in CIDP is valid in all EU member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland.